T-Cell Antigen Receptor

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed a trial-in-progress investigating autologous T-cell antigen coupler T cells targeting HER2 in relapsed or refractory solid tumors in a video interview with Healio.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses new allogeneic chimeric antigen receptor T-cell therapy data.

The UCLA Jonsson Cancer Center has begun enrolling patients in its latest chimeric antigen receptor T-cell immunotherapy trial for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma or chronic lymphocytic leukemia.